• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2021 Aug 16;S1201-9712(21)00661-5.
doi: 10.1016/j.ijid.2021.08.028. Online ahead of print.
Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020


Enyew Birru Tadesse[SUP] 1 [/SUP], Abduilhafiz A Endris[SUP] 2 [/SUP], Henok Solomon[SUP] 2 [/SUP], Mikias Alayu[SUP] 2 [/SUP], Adisu Kebede[SUP] 2 [/SUP], Kirubel Eshetu[SUP] 2 [/SUP], Gizaw Teka[SUP] 2 [/SUP], Biniyam Eskinder Seid[SUP] 3 [/SUP], Jelaludin Ahmed[SUP] 3 [/SUP], Sisay Alemayehu Abayneh[SUP] 3 [/SUP], Beyene Mogesc Hizikiyas Gerawork[SUP] 4 [/SUP], David Sugerman[SUP] 3 [/SUP], Zewdu Assefa[SUP] 2 [/SUP], Aschalew Abayneh[SUP] 2 [/SUP], Ebba Abate[SUP] 2 [/SUP], Lia Taddese[SUP] 2 [/SUP]



Affiliations

Abstract

Background: Ethiopia reported the first case of COVID-19 on March 13[SUP]th[/SUP], 2020 with community transmission ensue by mid-May. National, population-based serosurvey against anti-SARS-CoV-2 IgG was conducted to measure the prevalence of prior COVID-19 infections and better approximate the burden across major towns in Ethiopia.
Methods: We conducted a cross-sectional, population-based serosurvey from June 24 to July 8, 2020 in 14 major urban areas. Two-stage cluster sampling was used to randomly select enumeration areas and households. All persons aged ≥15 years were enrolled. Serum samples tested by Abbott™ ARCHITECT™ assay for SARS-CoV-2 IgG antibodies. National COVID-19 surveillance data on the median date of the serosurvey is analyzed for comparison.
Findings: Adjusted seroprevalence was 3.5% (95% CI: 3.2%-3.8%) after controlling for age, sex and test kit performance. Males (3.7%) and females (3.3%) were nearly equally infected, while middle-aged adults 40-65 years had the highest (4.0%) prevalence. Gambella (7.5%), Dire Dawa (6.2%) and Jigjiga (6.1%) were most affected towns. About 6.7% and 8.0% of seropositives had symptoms and chronic underlying illness, respectively. Surveillance system had identified 4,416 RT-PCR confirmed cases in Addis Ababa.
Interpretation: This serosurvey shows majority of urban Ethiopians remain uninfected with SARS-CoV-2. Most anti-SARS-CoV-2 IgG positive cases were asymptomatic with no underlying illness, keeping case detection to a minimum.

Keywords: Coronavirus Infections; Ethiopia; Immunoglobulin G; Seroepidemiologic studies; blood; epidemiology.
 
Back
Top Bottom